Track topics on Twitter Track topics that are important to you
(Université de Genève) The World Health Organization has deemed antibiotic resistance to be one of the greatest threats to human health, as bacteria become increasingly resistant and too few treatments are being developed to combat them. The research project DRIVE-AB, a consortium managed by the University of Geneva and AstraZeneca, has determined that a market entry reward of $1 billion per antibiotic globally could significantly increase the number of new antibiotics coming to the market.
Original Article: A new ecosystem approach to fight antibiotic resistanceNEXT ARTICLE
MRSA (methicillin-resistant Staphylococcus aureus)
MRSA (methicillin-resistant Staphylococcus aureus) is a family of bacteria with resistance to one or more major antibiotics. There are currently 17 different strains of MRSA. Two particular strains, EMRSA15 and EMRSA16 account for 96% of MRSA blood...
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...